{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:58:15Z","timestamp":1789005495005,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01418-2","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:10:42Z","timestamp":1764069042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Allogeneic hematopoietic cell transplantation in acute myeloid leukemia not in complete remission: outcomes and prognostic factors in a contemporary cohort"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5055-5317","authenticated-orcid":false,"given":"Shlomo","family":"Elias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-974X","authenticated-orcid":false,"given":"Samantha","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogechukwu","family":"Egini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moneeza","family":"Walji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvester","family":"Homsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arash","family":"Velayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6801-720X","authenticated-orcid":false,"given":"Sean","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5766","authenticated-orcid":false,"given":"Doris M.","family":"Ponce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-0358","authenticated-orcid":false,"given":"Parveen","family":"Shiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann A.","family":"Jakubowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza B.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1944-5053","authenticated-orcid":false,"given":"Sergio A.","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-2119","authenticated-orcid":false,"given":"Boglarka","family":"Gyurkocza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"1418_CR1","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute meyloid leukemia. Version 3.2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411."},{"key":"1418_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bbmt.2020.09.020","volume":"27","author":"B Dholaria","year":"2021","unstructured":"Dholaria B, Savani BN, Hamilton BK, Oran B, Liu HD, Tallman MS, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. 2021;27:6\u201320.","journal-title":"Transplant Cell Ther"},{"key":"1418_CR3","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"},{"key":"1418_CR4","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","volume":"381","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381:1728\u201340.","journal-title":"N Engl J Med"},{"key":"1418_CR5","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1200\/JCO.2013.52.8562","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, et al. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed\/refractory acute myeloid leukemia. J Clin Oncol. 2014;32:1919\u201326.","journal-title":"J Clin Oncol"},{"key":"1418_CR6","doi-asserted-by":"publisher","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","volume":"28","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W, Cahn J-Y, Cairo M, Camitta BM, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010;28:3730\u20138.","journal-title":"J Clin Oncol"},{"key":"1418_CR7","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377:2433\u201344.","journal-title":"N Engl J Med"},{"key":"1418_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/s41409-020-01082-z","volume":"56","author":"Y Mori","year":"2021","unstructured":"Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, et al. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant. 2021;56:853\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"1418_CR9","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/ajh.27726","volume":"100","author":"A Bazarbachi","year":"2025","unstructured":"Bazarbachi A, Galimard J-E, Dalle IA, Soci\u00e9 G, Versluis J, Wu D, et al. Challenging the adverse label: diverse outcomes of ELN 2022 adverse cytogenetic subgroups in acute myeloid leukemia patients allografted in first remission: from EBMT ALWP. Am J Hematol. 2025;100:1374\u201386.","journal-title":"Am J Hematol"},{"key":"1418_CR10","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","volume":"9","author":"K Lontos","year":"2025","unstructured":"Lontos K, Saliba RM, Kanagal-Shamanna R, \u00d6zcan G, Ramdial J, Chen G, et al. TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation. Blood Adv. 2025;9:2845\u201354.","journal-title":"Blood Adv"},{"key":"1418_CR11","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1002\/ajh.25934","volume":"95","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Labopin M, Angelucci E, Ciceri F, Diez-Martin JL, Bruno B, et al. Impact of total body irradiation- vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. Am J Hematol. 2020;95:1200\u20138.","journal-title":"Am J Hematol"},{"key":"1418_CR12","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41375-019-0671-x","volume":"34","author":"LM Morsink","year":"2020","unstructured":"Morsink LM, Bezerra ED, Othus M, Wood BL, Fang M, Sandmaier BM, et al. Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease. Leukemia. 2020;34:1701\u20135.","journal-title":"Leukemia"},{"key":"1418_CR13","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen-a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol. 2013;31:3549\u201356.","journal-title":"J Clin Oncol"},{"key":"1418_CR14","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3109\/10428199609051758","volume":"22","author":"RA Brown","year":"1996","unstructured":"Brown RA, Wolff SN, Fay JW, Pineiro L, Collins RH, Lynch JP, et al. High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group. Leuk Lymphoma. 1996;22:271\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1418_CR15","first-page":"324","volume":"3","author":"GD Long","year":"1997","unstructured":"Long GD, Amylon MD, Stockerl-Goldstein KE, Negrin RS, Chao NJ, Hu WW, et al. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies. Biol Blood Marrow Transplant. 1997;3:324\u201330.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1418_CR16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/bmt.2010.295","volume":"46","author":"AS Stein","year":"2011","unstructured":"Stein AS, O\u2019Donnell MR, Synold TW, Dagis AC, Tsirunyan A, Nademanee AP, et al. Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia. Bone Marrow Transplant. 2011;46:1256\u201362.","journal-title":"Bone Marrow Transplant"},{"key":"1418_CR17","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/bmt.2017.8","volume":"52","author":"B Gyurkocza","year":"2017","unstructured":"Gyurkocza B, Lazarus HM, Giralt S. Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy. Bone Marrow Transplant. 2017;52:1083\u201390.","journal-title":"Bone Marrow Transplant"},{"key":"1418_CR18","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/bmt.2016.325","volume":"52","author":"E Todisco","year":"2017","unstructured":"Todisco E, Ciceri F, Boschini C, Giglio F, Bacigalupo A, Patriarca F, et al. Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant. 2017;52:955\u201361.","journal-title":"Bone Marrow Transplant"},{"key":"1418_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1046\/j.1365-2141.2001.02519.x","volume":"112","author":"C Craddock","year":"2001","unstructured":"Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol. 2001;112:228\u201336.","journal-title":"Br J Haematol"},{"key":"1418_CR20","doi-asserted-by":"publisher","unstructured":"Nagler A, Labopin M, Swoboda R, Blaise D, Angelucci E, Vydra J, et al. Young (<35 years) haploidentical versus old (\u226535 years) mismatched unrelated donors and vice versa for allogeneic stem cell transplantation with post-transplant cyclophosphamide in patients with acute myeloid leukemia in first remission: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2024. https:\/\/doi.org\/10.1038\/s41409-024-02400-5.","DOI":"10.1038\/s41409-024-02400-5"},{"key":"1418_CR21","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","volume":"6","author":"R Shouval","year":"2019","unstructured":"Shouval R, Fein JA, Labopin M, Kr\u00f6ger N, Duarte RF, Bader P, et al. Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis. Lancet Haematol. 2019;6:e573\u201384.","journal-title":"Lancet Haematol"},{"key":"1418_CR22","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1158\/1078-0432.CCR-22-0809","volume":"28","author":"A Nagler","year":"2022","unstructured":"Nagler A, Ngoya M, Galimard J-E, Labopin M, Bornh\u00e4user M, Stelljes M, et al. Longitudinal outcome over two decades of unrelated allogeneic stem cell transplantation for relapsed\/refractory acute myeloid leukemia: an ALWP\/EBMT analysis. Clin Cancer Res. 2022;28:4258\u201366.","journal-title":"Clin Cancer Res"},{"key":"1418_CR23","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","volume":"388","author":"J Bola\u00f1os-Meade","year":"2023","unstructured":"Bola\u00f1os-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023;388:2338\u201348.","journal-title":"N Engl J Med"},{"key":"1418_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3324\/haematol.2016.147645","volume":"101","author":"HT Kim","year":"2016","unstructured":"Kim HT, Zhang M-J, Woolfrey AE, St Martin A, Chen J, Saber W, et al. Donor and recipient sex in allogeneic stem cell transplantation: What really matters. Haematologica. 2016;101:1260\u20136.","journal-title":"Haematologica"},{"key":"1418_CR25","doi-asserted-by":"publisher","first-page":"e007635","DOI":"10.1136\/jitc-2023-007635","volume":"12","author":"O Penack","year":"2024","unstructured":"Penack O, Luft T, Peczynski C, Benner A, Sica S, Arat M, et al. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study. J Immunother Cancer. 2024;12:e007635.","journal-title":"J Immunother Cancer"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01418-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01418-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T11:10:44Z","timestamp":1764069044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01418-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1418"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01418-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"25 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SE received honoraria from Novartis and Gilead. MS reports consultancy for CVS Caremark, advisory for A28 Therapeutics, and patents pertaining to the intestinal microbiome and CAR T cell therapy\u2014US 17\/229,184; US 391 63\/303,461. M-AP reports honoraria from Adicet, Allogene, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Kite\/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Pierre Fabre, Sanofi, Syncopation, Takeda, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences. He has ownership interests in Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Genmab, Incyte, Kite\/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. DMP has served as an advisory board member for Evive Biotechnology (Shanghai) Ltd; has consulted, received honorarium from, or participated in the advisory boards for Sanofi, Ceramedix, and Incyte Corporation, and received research funding from Sanofi and Incyte. All other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Ethical approval for this retrospective study was obtained from the Institutional Review Boards at MSKCC (16-505 A(22)) and Stanford University (8903). The requirement for informed consent was waived by the ethics committee due to the retrospective nature of the study and the use of de-identified data. No identifiable images of human participants are included in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"208"}}